Tivic Health Systems Touts Entolimod Phase 3 ARS Path, Eyes BLA in 2027-2028 at Conference

Tivic Health Systems (NASDAQ: TIVC) outlined its strategy to advance what it described as late-stage, "highly de-risked" biopharma assets over the next 12 to 24 months, with a primary focus on Entolimod, a Toll-like receptor 5 (TLR5) agonist. Speaking during the event, company executive Michael said the company is focused on immune therapies intended to improve